BG Medicine, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported total revenues of $334,000 against $695,000 a year ago. Loss from operations was $1,026,000 against $2,233,000 a year ago. Net loss was $1,023,000 against $2,397,000 a year ago. Net loss attributable to common shareholders was $2,627,000 against $2,397,000 a year ago. Net loss per share attributable to common shareholders basic and diluted was $0.27 against $0.28 per share a year ago.

For the nine months, the company reported total revenues of $1,276,000 against $2,233,000 a year ago. Loss from operations was $3,728,000 against $6,151,000 a year ago. Net loss was $4,401,000 against $6,744,000 a year ago. Net loss attributable to common shareholders was $6,005,000 against $6,744,000 a year ago. Net loss per share attributable to common shareholders basic and diluted was $0.66 against $0.84 per share a year ago. Net cash flows used in operating activities was $2,550,000 against $7,097,000 a year ago.